Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Annals of Oncology

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDL056PMID 16565212
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral Alkylating Agents for Breast Cancer Therapy

  2012cited by this paper
• O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases

  2004cited by this paper
• Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study

  2004cited by this paper
• MGMT: its role in cancer aetiology and cancer therapeutics

  2004cited by this paper
• Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

  2003cited by this paper
• Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

  2003cited by this paper
• Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases.

  2001cited by this paper
• A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

  2000cited by this paper
• Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells.

  2000cited by this paper
• Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Front‐line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma

  1999cited by this paper
• Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials.

  1997cited by this paper
• Response of brain metastases from breast cancer to systemic chemotherapy

  1992cited by this paper
• Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

  1987cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper

• Mechanistic role of stromal cancer-associated fibroblasts in tumorigenesis and brain metastasis: Highlighting drug resistance and targeted therapy.

  2025cites this paper
• Treatment strategies for leptomeningeal disease in patients with breast cancer.

  2025cites this paper
• Controlling Temozolomide Efficacy by Light-Dependent Inhibition of O6‑Methylguanine DNA Methyltransferase.

  2025cites this paper
• Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis

  2025influential citation
• Temozolomide alleviates breast carcinoma via the inhibition of EGFR/ERK/ MMP-1 pathway with induction of apoptotic events

  2024cites this paper
• Prevention of Brain Metastases: A New Frontier

  2024cites this paper
• Predicting drug outcome of population via clinical knowledge graph

  2024cites this paper
• Revisiting Temozolomide's role in solid tumors: Old is gold?

  2024cites this paper
• Systematic review of the management of brain metastases from hormone receptor positive breast cancer

  2023cites this paper
• Systemic treatments for breast cancer brain metastasis

  2023cites this paper
• Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study

  2023cites this paper
• CMA mediates resistance in breast cancer models

  2023cites this paper
• Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.

  2023cites this paper
• Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases

  2022cites this paper
• Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment

  2022cites this paper
• Towards updated understanding of brain metastasis.

  2022cites this paper
• Exploiting DNA Replication Stress as a Therapeutic Strategy for Breast Cancer

  2022cites this paper
• Novel Synergistic Combination of Pamidronate and Temozolomide for Breast Cancer Therapeutics.

  2022cites this paper
• Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma

  2021cites this paper
• Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report

  2021cites this paper
• Outpatient fractionated ICE protocol in relapsed/refractory lymphomas: Efficacy and safety

  2021cites this paper
• Central Nervous System Malignancies

  2021cites this paper
• Cardiac Involvement of Adult T Cell Leukemia/Lymphoma

  2021cites this paper
• Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations

  2021cites this paper
• Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

  2021cites this paper
• Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma

  2021cites this paper
• Brain metastasis models: What should we aim to achieve better treatments?

  2020cites this paper
• Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma

  2020cites this paper
• Comparison of the efficacy and impact of GEMOX and GDP in the treatment of patients with non-Hodgkin's lymphoma.

  2020cites this paper
• Systemic Therapy of Brain Metastases: Breast Cancer

  2020cites this paper
• Saudi Lymphoma Group‘s Clinical Practice Guidelines for Diagnosis, Management and Follow-up of Patients with Various Types of Lymphoma during the Coronavirus Disease 2019 Pandemic

  2020cites this paper
• PECAM is an effective and safe anthracycline-containing third-line regimen for patients with relapsed or refractory non-Hodgkin lymphoma

  2020cites this paper
• Metastasis to the Central Nervous System.

  2020cites this paper
• The management of elderly patients with brain metastases from breast cancer

  2020cites this paper
• Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma

  2020cites this paper
• The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience

  2020cites this paper
• Gemcitabine, dexamethasone, and cisplatin salvage in relapsed lymphomas: A single institutional experience

  2020cites this paper
• Rituximab-Mediated Complement-Dependent Cytotoxicity Enhanced by Gemcitabine in Older Patients with Previously Rituximab-Treated Diffuse Large B-Cell Lymphoma: Study Protocol.

  2019cites this paper
• Central Nervous System Metastases in HER2-Positive Breast Cancer

  2019cites this paper
• Prognostic value of age-adjusted international prognostic index in patients with relapsed or refractory diffuse large b-cell lymphoma - a single centre experience

  2019cites this paper
• The Current and Evolving Role of Radiation Therapy for Central Nervous System Metastases from Breast Cancer

  2019cites this paper
• Peripheral T-cell Lymphomas

  2019cites this paper
• Brain metastases

  2019cites this paper
• Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma

  2019cites this paper
• Systemic Therapy of Central Nervous System Metastases of Breast Cancer

  2019cites this paper
• Neurological Complications of Breast Cancer and Its Treatment

  2018cites this paper
• Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

  2018cites this paper
• Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro

  2018cites this paper
• Systemic therapy for brain metastases.

  2018cites this paper
• Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis

  2018cites this paper
• Definitive salvage chemotherapy for the treatment of refractory/relapsed non-Hodgkin lymphoma, a single center experience

  2018cites this paper
• Enzymes in the Base Excision Repair Pathway as Targets for Small Molecule Mediated Therapeutics

  2017cites this paper
• Durable remission of brain metastasis of hormone receptor-positive breast cancer with temozolomide and hormone therapy : two case reports and literature review

  2017cites this paper
• Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management.

  2017cites this paper
• Biweekly dose‐dense gemcitabine–oxaliplatin and dexamethasone for relapsed/refractory aggressive non‐Hodgkin lymphoma: A multicenter, single‐arm, phase II trial

  2016cites this paper
• Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?

  2016cites this paper
• A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

  2016cites this paper
• Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

  2016cites this paper
• Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases

  2016cites this paper
• Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.

  2015cites this paper
• Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells

  2015cites this paper
• Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.

  2015cites this paper
• Breast cancer brain metastases: the last frontier

  2015cites this paper
• Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma

  2015cites this paper
• Long-term Survival of Patients with Breast Cancer and Brain Metastases: ‘The experience of the 2nd Oncology Department of Metropolitan Hospital and a brief review of the literature’

  2015cites this paper
• [Systemic treatment of brain metastases from breast cancer].

  2015cites this paper
• Long-term Survival of Patients with Breast Cancer and Brain Metastases: ‘The experience of the 2nd Oncology Department of Metropolitan Hospital and a brief review of the literature’

  2015cites this paper
• Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.

  2015cites this paper
• Current approaches to the treatment of metastatic brain tumours

  2014cites this paper
• Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner

  2014influential citation
• [Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].

  2014cites this paper
• Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update

  2014cites this paper
• Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

  2014cites this paper
• Brain metastasis: New opportunities to tackle therapeutic resistance

  2014cites this paper
• A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo

  2014cites this paper
• Estudio de adecuación de la prescripción de quimioterapia en cáncer de mama en un hospital de tercer nivel

  2014cites this paper
• Brain metastases from esophageal cancer: clinical review of 26 cases.

  2014cites this paper
• Place de l’association radiothérapie encéphalique et thérapies systémiques dans le traitement des métastases cérébrales d’un cancer du sein

  2014cites this paper
• Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline

  2013cites this paper
• Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

  2013cites this paper
• Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy

  2013cites this paper
• Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice

  2013cites this paper
• Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.

  2013cites this paper
• Breast cancer brain metastases: new directions in systemic therapy

  2013cites this paper
• Temozolomide and unusual indications: review of literature.

  2013cites this paper
• Clinical Trials for Breast Cancer with Brain Metastases: Challenges and New Directions

  2013cites this paper
• Mechanisms and insights into drug resistance in cancer

  2013cites this paper
• Clinical Significance of PARP-1 Inhibitors in Cancer Chemotherapy

  2013cites this paper
• DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.

  2013cites this paper
• A phase 2 study of epothilone B analog BMS‐247550 (NSC 710428) in patients with relapsed aggressive non‐Hodgkin lymphomas

  2013cites this paper
• New insights and emerging therapies for breast cancer brain metastases.

  2012cites this paper
• Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases

  2012cites this paper
• Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial.

  2012cites this paper
• Treatment of Breast Cancer Brain Metastases

  2012cites this paper
• Chapter 7 – Chemotherapy for Brain Tumors

  2012cites this paper
• Breast cancer metastasis to the central nervous system

  2012cites this paper
• Development of molecular imaging probes for positron emission tomography

  2012cites this paper
• Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience

  2012cites this paper
• DNA Polymerase β as a Novel Target for Chemotherapeutic Intervention of Colorectal Cancer

  2011cites this paper
• Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?

  2011cites this paper